Distinct Pathways, Shared Progress: Metabolic/Genetic Disorders & Biliary Physiology

Nov 09 2025
Convention Center: Room 145, Level 1
8:00 AM - 9:30 AM

World Class Speakers

Pavel Strnad, MD
Abstract Presenter

Pavel Strnad, MD
Vik Meadows, PhD
Abstract Presenter

Vik Meadows, PhD

University of Pittsburgh
Michael L Schilsky, MD, FAASLD
Moderator

Michael L Schilsky, MD, FAASLD

Yale University Medical Center
Grace L Guo, MBBS, PhD
Moderator

Grace L Guo, MBBS, PhD

Rutgers University

Description

This session highlights innovations from molecular mechanisms to drug development and clinical trials in biliary physiology and genetic and metabolic conditions. This session will spotlight cholangiocyte biology from scaffolding to repair. These research presentations will provide insights into mechanisms and therapeutics for A1AT deficiency, Wilson Disease, and hemachromatosis. 

Journey Maps

Presentations

8:15 AM - 8:30 AM
Apr 29 2026
Washington, D.C.

Fazirsiran is effective in early and advanced fibrosis in patients with alpha-1 antitrypsin deficiency-associated liver disease

Pavel Strnad, MD , Abstract Presenter
Basic Science
8:30 AM - 8:45 AM
Apr 29 2026
Washington, D.C.

Inducible dual loss of β- and γ-catenin in bile ducts leads to cholestatic injury and mortality or repair based on the extent of cell junction loss  

Vik Meadows, PhD , Abstract Presenter
Basic Science

Objectives

  • Evaluate emerging therapies for metabolic and genetic liver disease.
  • Describe basic science mechanisms of cholangiocyte development and repair and their implications for therapeutic targets.
  • Discuss basic, translational, and clinical studies for treatment of biliary disorders and genetic/metabolic liver disease.